Fwd: Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer (The San Francisco Examiner)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Feb 19, 2008 at 8:35 AM
Subject: Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer (The San Francisco Examiner)
To: mesothelioma77@gmail.com


WAYNE, N.J. and EMERYVILLE, Calif., Feb. 18 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that a Phase 3 trial evaluating Nexavar(R) (sorafenib) tablets in patients with non-small cell lung cancer (NSCLC) was stopped early following a planned interim analysis, when the independent Data Monitoring Committee (DMC) concluded that the ...

Mon, 18 Feb 2008 16:20:33 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=14fcg4p3f/*http%3A//www.examiner.com/p-117014~Bayer_and_Onyx_Provide_Update_on_Phase_3_Trial_of_Nexavar_in_Patients_With_Non_Small_Cell_Lung_Cancer.html
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc